Emerging Infectious Disease ISSN: 1080-6059

Monitoring Antimicrobial Use and Resistance: Comparison with a National Benchmark on Reducing Vancomycin Use and Vancomycin-Resistant Enterococci

Scott K. Fridkin*, Rachel Lawton*, Jonathan R. Edwards*, Fred C. Tenover*, John E. McGowan†, Robert P. Gaynes*, and the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project, and the National Nosocomial Infections Surveillance (NNIS) System Hospitals

Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Emory University, Atlanta, Georgia, USA

Main Article

Figure 2

Difference (postintervention period minus pre-intervention) in rate of vancomycin use and prevalence of vancomycin-resistant enterococci (VRE) (%) in 35 intensive-care units (ICUs) testing >10 clinical isolates of Enterococci spp., Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE), January 1996–July 1999. Squares represent ICUs reporting a prescriber practice change targeted in the specific ICUs (i.e., ICU-specific practice change). DDD, defined daily doses.

Figure 2. . Difference (postintervention period minus pre-intervention) in rate of vancomycin use and prevalence of vancomycin-resistant enterococci (VRE) (%) in 35 intensive-care units (ICUs) testing >10 clinical isolates of Enterococci spp., Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE), January 1996–July 1999. Squares represent ICUs reporting a prescriber practice change targeted in the specific ICUs (i.e., ICU-specific practice change). DDD, defined daily doses.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.